---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-123321"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:25:41.989657+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology Q3 net loss $54.4M; cash $455.3M; ziftomenib data expected early 2025

## Summary
- Net loss $54.4M in Q3 2024 vs $38.6M in Q3 2023; R&D expenses $41.7M.
- Cash, cash equivalents and investments $455.3M as of Sep 30, 2024; runway into 2027.
- Topline results from registration-directed ziftomenib trial in R/R NPM1-mutant AML expected early 2025.
- Phase 1b expansion study of ziftomenib enrolling at 600 mg; 45 patients enrolled since Aug 2024.
- First patient dosed in KO-2806 + adagrasib in KRAS G12C NSCLC; GIST proof-of-concept study planned 1H 2025.

## SEC filing metadata
- accession: 0000950170-24-123321
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000095017024123321/0000950170-24-123321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000095017024123321/kura-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-123321
- JSON: https://secwatch.observer/filing/0000950170-24-123321.json
- Plain text: https://secwatch.observer/filing/0000950170-24-123321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.